Education
About Us
Working with TipRanks
Follow Us
RZG - ETF AI Analysis
Top Page
Invesco S&P Smallcap 600 Pure Growth ETF (RZG)
Rating:69Neutral
Price Target:―
Positive Factors
Strong Top Holdings
Several of the ETF’s largest positions, such as Protagonist Therapeutics and InterDigital, have delivered strong year-to-date performance, supporting overall returns.
Sector Diversification
The ETF spreads its investments across ten sectors, including Health Care, Industrials, and Financials, reducing reliance on any single industry.
Reasonable Expense Ratio
The ETF’s expense ratio of 0.35% is competitive for a specialized fund, helping investors retain more of their returns.
Negative Factors
High Geographic Concentration
The ETF is heavily focused on U.S. companies, with over 99% exposure, limiting diversification across global markets.
Underperforming Holdings
Some top holdings, like Veracyte, have shown weak year-to-date performance, which could drag on the fund’s overall momentum.
Small Asset Base
With just over $104 million in assets under management, the ETF may face liquidity challenges compared to larger funds.
RZG vs. SPDR S&P 500 ETF (SPY)
AUM108.39M
RegionNorth America
Expense Ratio0.35%
Beta0.99
IssuerInvesco
Inception DateMar 01, 2006
Dividend Yield0.47%
Asset ClassEquity
Index TrackedS&P Small Cap 600 Pure Growth
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume3,421
30 Day Avg. Volume3,934
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
66.45Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering136
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
RZG Summary
The Invesco S&P SmallCap 600 Pure Growth ETF (RZG) is a fund that focuses on small-cap companies in the U.S. with strong growth potential. It tracks the S&P SmallCap 600 Pure Growth Index, which includes businesses showing rapid earnings and sales growth. Some of its top holdings are Protagonist Therapeutics and InterDigital. Investors might consider RZG for its potential to deliver high returns by tapping into the innovation and agility of smaller companies. However, it’s important to know that small-cap stocks can be more volatile, meaning their prices can rise and fall quickly.
How much will it cost me?The Invesco S&P SmallCap 600 Pure Growth ETF (RZG) has an expense ratio of 0.35%, which means you’ll pay $3.50 per year for every $1,000 invested. This is slightly higher than average because it is designed to track a specific niche index of small-cap growth companies, requiring more active management. It’s a good option if you’re looking for targeted exposure to high-growth small-cap stocks.
What would affect this ETF?The ETF's focus on U.S. small-cap growth companies means it could benefit from economic expansion, increased innovation, and favorable conditions for entrepreneurial businesses, particularly in sectors like health care and technology. However, it may face challenges from rising interest rates, which can increase borrowing costs for smaller companies, or economic slowdowns that disproportionately impact small-cap stocks. Regulatory changes in key sectors like health care or financials could also influence performance.
RZG Top 10 Holdings
The Invesco S&P SmallCap 600 Pure Growth ETF (RZG) is leaning heavily into health care and industrials, which together make up over 40% of the fund’s weight. Protagonist Therapeutics is a standout, rising steadily thanks to strong momentum and solid financial health, while Dycom is also climbing, buoyed by strategic acquisitions and revenue growth. On the flip side, DXP Enterprises is lagging, with bearish technical trends holding it back despite record sales. The fund’s U.S.-centric focus and small-cap growth tilt make it a dynamic but potentially volatile choice for investors seeking agility and innovation.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Protagonist Therapeutics | 3.10% | $3.34M | $5.96B | 132.11% | 68 Neutral | |
| InterDigital | 2.30% | $2.48M | $9.12B | 82.28% | 76 Outperform | |
| Corcept Therapeutics | 1.79% | $1.93M | $9.26B | 58.83% | 76 Outperform | |
| Veracyte | 1.67% | $1.80M | $3.39B | -0.88% | 76 Outperform | |
| DXP Enterprises | 1.66% | $1.79M | $1.71B | 37.39% | 71 Outperform | |
| Acadian Asset Management | 1.64% | $1.77M | $1.70B | 58.33% | 66 Neutral | |
| Krystal Biotech | 1.62% | $1.75M | $7.09B | 49.50% | 80 Outperform | |
| Powell Industries | 1.58% | $1.70M | $4.08B | 33.76% | 76 Outperform | |
| Dycom | 1.51% | $1.62M | $10.01B | 92.66% | 80 Outperform | |
| Enova International | 1.45% | $1.56M | $4.03B | 61.20% | 71 Outperform |
RZG Technical Analysis
Positive
―
Price Trends
54.16
Positive
53.66
Positive
50.78
Positive
Market Momentum
0.57
Negative
62.70
Neutral
89.12
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For RZG, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 54.01, equal to the 50-day MA of 54.16, and equal to the 200-day MA of 50.78, indicating a bullish trend. The MACD of 0.57 indicates Negative momentum. The RSI at 62.70 is Neutral, neither overbought nor oversold. The STOCH value of 89.12 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RZG.
RZG Peer Comparison
Comparison Results
Performance Comparison
RZG
Invesco S&P Smallcap 600 Pure Growth ETF
56.08
3.97
7.62%
FYX
First Trust Small Cap Core AlphaDEX Fund
―
―
―
VIOG
Vanguard S&P Small-Cap 600 Growth ETF
―
―
―
ISCG
iShares Morningstar Small-Cap Growth ETF
―
―
―
FYC
First Trust Small Cap Growth AlphaDEX Fund
―
―
―
JSML
Janus Henderson Small Cap Growth Alpha ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents